IPP Bureau
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
By IPP Bureau - February 08, 2022
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Merck KGaA restructures life science business to support long-term growth
By IPP Bureau - February 08, 2022
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Granules India Q3FY22 PAT at Rs 100.88 cr.
By IPP Bureau - February 08, 2022
Granules India has reported consolidated financial results for the period ended December 31, 2021
AsterDM Healthcare Q3FY22 PAT at Rs 148.34 cr.
By IPP Bureau - February 08, 2022
Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021
Suven Pharma Q3FY22 PAT at Rs. 160.06 crore
By IPP Bureau - February 08, 2022
Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
Lupin receives approval from USFDA for Arformoterol Tartrate inhalation
By IPP Bureau - February 08, 2022
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
Origin Materials and Minafin form strategic partnership for biobased chemicals
By IPP Bureau - February 08, 2022
The partnership includes multiple collaboration areas and is an important milestone for bringing cost-competitive biobased products to the market, with applications in the pharmaceutical, agricultural, cosmetics and personal care, and automotive industries
Biosynthetic Technologies raises $7.5 million
By IPP Bureau - February 08, 2022
Biosynthetic Technologies produces estolides, a new class of biobased synthetic oils used in a number of applications, including motor oil, industrial lubricants, pharmaceuticals, and personal care.
India grants Emergency Use Authorisation to Sputnik Light
By IPP Bureau - February 07, 2022
This is the ninth Covid-19 vaccine approved in India
Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
By IPP Bureau - February 07, 2022
Key takeaways of recent quarter & conference call highlights
Lay Sciences launch ImmynlgY, an oral antibody to neutralize Covid-19
By IPP Bureau - February 07, 2022
ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status
Venus Remedies join AMR alliance to combat global health threat
By IPP Bureau - February 07, 2022
The antimicrobial resistance alliance recently released its third Progress Report, reflecting on collective achievements from the life sciences industry
Rahul Guha to join Thyrocare Technologies as MD & CEO
By IPP Bureau - February 07, 2022
Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice
WHO Goodwill Ambassador calls for renewed focus on leprosy
By IPP Bureau - February 07, 2022
The campaign aims to bring back focus on leprosy case detection, treatment and rehabilitation; especially in the context of neglect brought in by Covid-19 pandemic
Redcliffe Labs appoints Abhay Singavi as Chief Business Officer
By IPP Bureau - February 07, 2022
Takes charge to lead business innovation, strategy, alliance & partnerships
